Therapeutic and Protective Effects of a New Heterocyclic Compound in Diabetes Complicated by Ocular Diseases

The new heterocyclic compound 4-(4-aminophenyl)morpholin-3-one (1), designed using 2-(2-chloroethoxy)acetyl chloride (2) and 4-nitroaniline (3) as a raw material, was produced through multiple formation route in success and evidently characterized through 1H NMR, IR, together with crystallography of single crystal X-ray. Besides, the aim of this investigation was to assess the combined treatment of diabetes mellitus along with ocular diseases, and to analyze its mechanism. First of all, the determination of real time RT-PCR was accomplished and the GLP-1 receptor on endothelial cells. Then, the accumulation of AGE in the retinal capillary pericytes was detected with ELISA assay.